Jeremy A Schafer
Overview
Explore the profile of Jeremy A Schafer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A, Starner C, Gunderson B, Schafer J, Qiu Y, Gleason P
J Manag Care Pharm
. 2012 Dec;
18(9):690-700.
PMID: 23206212
Unlabelled: Background: In 2006, pharmacies began offering select generic prescription drugs at discount prices (e.g., $4 for a 30-day supply) through nonmembership and membership programs. As part of the contract...
2.
Tungol A, Rademacher K, Schafer J
J Manag Care Pharm
. 2011 Nov;
17(9):685-94.
PMID: 22050393
Background: Hepatitis C virus (HCV) is the most common chronic bloodborne illness in the United States. The incidence of acute hepatitis C in the United States peaked near 50,000 cases...
3.
Schafer J, Gunderson B, Gleason P
J Manag Care Pharm
. 2010 Nov;
16(9):713-7.
PMID: 21067257
No abstract available.
4.
Schafer J, Kjesbo N, Gleason P
J Manag Care Pharm
. 2010 Jul;
16(6):402-16.
PMID: 20635831
Background: Two autoimmune biologics were recently approved by the FDA: ustekinumab in September 2009 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy...
5.
Schafer J, Kjesbo N, Gleason P
Cardiovasc Ther
. 2010 Jan;
28(1):38-47.
PMID: 20074258
Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting more than 2.2 million Americans. ACC/AHA/ESC guidelines for the management of patients with AF recommend amiodarone for maintaining sinus rhythm....
6.
Association of prescription abandonment with cost share for high-cost specialty pharmacy medications
Gleason P, Starner C, Gunderson B, Schafer J, Sarran H
J Manag Care Pharm
. 2009 Oct;
15(8):648-58.
PMID: 19803554
Background: In 2008, specialty medications accounted for 15.1% of total pharmacy benefit medication spending, and per member expenditures have increased by 11.1% annually from 2004 to 2008 within a commercially...
7.
Schafer J, Kjesbo N, Gleason P
J Manag Care Pharm
. 2009 May;
15(4):335-43.
PMID: 19422273
Background: Cardiovascular disease, including acute coronary syndromes (ACS) comprising ST-elevation and non-ST-elevation myocardial infarction (STEMI/NSTEMI) and unstable angina (UA), remains the leading cause of death in the United States. The...
8.
Starner C, Schafer J, Heaton A, Gleason P
J Manag Care Pharm
. 2008 Aug;
14(6):523-31.
PMID: 18693776
Background: Rosiglitazone was approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes in 1999. The unique mechanism of action and low risk of hypoglycemia contributed to...
9.
Gleason P, Walters C, Heaton A, Schafer J
J Manag Care Pharm
. 2007 Jul;
13(5):420-5.
PMID: 17605513
Background: Telithromycin (Ketek) was approved in April 2004 for the treatment of acute bacterial exacerbations of chronic bronchitis (ABECB), bacterial sinusitis, and community-acquired pneumonia. The approval of telithromycin was controversial...
10.
Schafer J, Mateo N, Parlier G, Rotschafer J
Pharmacotherapy
. 2007 Mar;
27(4):542-5.
PMID: 17381381
Drug-induced anaphylaxis remains a relatively infrequent event. However, penicillin and associated beta-lactam antibiotics remain a primary cause of anaphylaxis. Penicillin allergies are undoubtedly overreported, and patients with suspected penicillin allergy...